To address this, a recent study developed a dual-targeting CAR-T cell (GPC3/PD-1) that recognizes GPC3 combining antigen-specific targeting PD-1 to block immune checkpoint, potentially overcoming ICI resistance by directly targeting tumor cells while modulating the TME. Here, GPC3 is linked to neoplasm.